MedTrace Logo

Midodrine and Albumin for Cirrhotic Patients With Functional Renal Impairment

NCT01133795 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 7

Last updated 2016-08-18

No results posted yet for this study

Summary

The objective of the study was evaluate the effect of administration of midodrine and albumin on renal function in patients with cirrhosis and creatinine greater than 1,2mg/dl.

Conditions

  • Cirrhosis
  • Renal Failure

Interventions

DRUG

Midodrine plus Albumin

MIdodrine 10mg tid for 12 weeks. Albumin 40g every 14 days for 12 weeks

Sponsors & Collaborators

  • Hospital Clinic of Barcelona

    lead OTHER

Principal Investigators

  • Pere Ginès, MD · Hospital Clinic of Barcelona

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-02-28
Primary Completion
2016-06-30
Completion
2016-06-30

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01133795 on ClinicalTrials.gov